IDH2 and acute myeloid leukemia: To identify novel therapeutic agents for the treatment of AML harboring IDH mutation, we first performed transcriptomic analyses of two published independent cohorts of AML patients (GSE14468 [17], TCGA) and HL60 AML cell line expressing either IDH1R132H or IDH1WT (Table S1) [4].